Sleep Peptides: What the Research Literature Actually Says

Last reviewed: September 2026

“Sleep peptides” means three different things on Google, and only one of them is a research topic. The first is a shelf of consumer supplements — melatonin and amino-acid blends with “peptides” in the product name — which have nothing to do with the research literature. The second is clinic marketing, in which the same handful of compounds are sold to people with promises attached. The third is a real body of laboratory science, running from the isolation of a sleep-associated peptide from rabbit blood in 1977 to modern EEG and circadian assays in animal models, which asks a much narrower question: what do these molecules do to sleep architecture in the organisms that have been studied? This guide covers only the third. It reports findings by the model they came from, it is candid where the literature is thin or unresolved, and it never turns a rodent EEG trace into a suggestion for a person.

Why “sleep peptides” is a research topic, not a supplement aisle

The compounds below share one property: at some point a study measured what they did to sleep — usually slow-wave (delta) sleep, sometimes circadian timing — in an animal or in a small early human experiment. That is the entire basis for grouping them, and it is a research classification, not a product category. In Canada none of them is authorized for human use as a sleep aid or as anything else; research-grade versions are supplied to laboratories as lyophilised reagents labelled for research use only, on the same terms as any other research peptide. The supplement products that share the search term are a different class of product under different rules, and the clinic pages that promise outcomes are making claims the literature does not support. What follows is the literature.

Peptides studied in sleep research

If the question is “which peptide has the most sleep research behind it,” the honest answer is the one that was named for it. Ranked by the depth of the literature rather than by any claim about people:

DSIP (delta sleep-inducing peptide)

DSIP is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 by Schoenenberger and Monnier from the cerebral venous blood of rabbits in electrically induced sleep. The name records what the discoverers observed: infused into recipient rabbits, the peptide increased delta-wave EEG activity, the signature of slow-wave sleep. Over the following two decades the finding was pursued in rabbits, rats, cats and mice, and in a handful of small early human studies, with results that the field itself describes as inconsistent — sleep-promoting effects were reported in several species, some replications found little or nothing, and the mechanism was never settled. DSIP has no identified receptor; it is rapidly degraded in circulation; and a substantial part of the later literature concerns stress-hormone and pain-model endpoints rather than sleep at all. The most accurate summary is that DSIP is the most-studied sleep-associated peptide and remains the least understood. It is available for laboratory research in Canada as DSIP, 5 mg lyophilised vial.

Epitalon

Epitalon (also spelled epithalon) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — developed by Vladimir Khavinson’s group in St Petersburg as a defined analogue of epithalamin, a pineal-gland extract. Its sleep-adjacent literature concerns circadian biology: in aged rats and in aged rhesus monkeys, epitalon administration has been reported to restore a more youthful night-time rhythm of melatonin secretion and to normalise related circadian markers that flatten with age. The studies are almost entirely from one research lineage, are conducted in aged animals rather than in models of disturbed sleep, and measure hormone rhythms rather than sleep itself; there is no controlled human sleep trial. Epitalon is a circadian-research compound with a thin, single-source evidence base, and that is how it should be described. It is stocked as epitalon, 10 mg lyophilised vial.

GH-axis peptides: CJC-1295, ipamorelin and tesamorelin

The growth-hormone-releasing peptides appear on sleep-research lists for a specific and well-documented reason: in mammals, growth-hormone secretion and slow-wave sleep are coupled, with the largest GH pulse of the day occurring during the first slow-wave episode of the night, and both are driven by growth-hormone-releasing hormone (GHRH). Studies in rats and in humans through the 1990s reported that GHRH administration increased slow-wave sleep, while GHRH antagonism reduced it. CJC-1295 and tesamorelin are GHRH analogues, and ipamorelin is a growth-hormone secretagogue acting at a different receptor; each is therefore discussed in the sleep literature as a tool for probing the GHRH–slow-wave-sleep relationship, not as a sleep agent. The research-grade blends are CJC-1295 + ipamorelin and tesamorelin + ipamorelin; how the four GH-axis compounds compare by receptor and evidence depth is in sermorelin vs ipamorelin vs tesamorelin.

GHK-Cu and others sometimes listed

Clinic listicles ranking “peptides for sleep” routinely include GHK-Cu, the copper tripeptide. Its sleep-specific literature is essentially non-existent: GHK-Cu’s research base is in wound models, fibroblast culture and gene-expression profiling, and it appears on sleep lists because gene-expression datasets show it touching a great many pathways, not because any study measured sleep. The same is true of most other names that get added to these lists. This section exists to say so. If GHK-Cu interests you, the copper peptides guide and the GHK-Cu research peptide page describe what its literature actually covers.

How sleep-peptide studies are actually run

The methodology is what separates the literature from the marketing. In animal sleep studies the primary instrument is the electroencephalogram: electrodes implanted in a rat or rabbit record cortical activity continuously, the recording is scored into wake, non-REM and REM sleep in short epochs, and the power of the delta band (roughly 0.5–4 Hz) during non-REM sleep is computed as the measure of slow-wave sleep intensity. A compound is administered — intraperitoneally, intracerebroventricularly or by another defined route — and the EEG in the hours afterward is compared against vehicle controls in the same animals. Circadian studies use a different toolkit: animals are kept under controlled light–dark cycles, and melatonin or other hormones are sampled at fixed times across the day and night to build a rhythm curve, which can then be compared between treated and untreated groups. In-vitro work is narrower still — receptor-binding assays, stability in plasma or gastric fluid, and gene-expression profiling in cultured cells. Every finding in the section above comes from one of these designs, and each design answers a question about that model only.

Regulatory status in Canada

Sourcing sleep-research peptides in Canada

The checks are the same as for any research peptide, and they matter more for compounds like DSIP and epitalon whose stability in solution is limited: a per-batch Certificate of Analysis from a named independent laboratory reporting HPLC purity and mass-spectrometry identity, a batch number on the vial that matches the published report, cold storage and dark handling from dispatch to bench, and a supplier whose product pages stay inside the research framework. Quantum’s batches are tested by Peptide Test Canada with the reports on the Certificate of Analysis hub; the sourcing process is walked through in how to buy research peptides in Canada, and the catalogue is in the shop.

Frequently asked questions

What are sleep peptides?

In the research literature, “sleep peptides” are peptides whose effects on sleep architecture or circadian rhythm have been measured in laboratory studies — principally DSIP, epitalon and the GH-axis peptides such as CJC-1295, tesamorelin and ipamorelin. They are laboratory research materials, distinct from consumer “peptide” sleep supplements, and none is authorized for human use in Canada.

What is the most studied peptide in sleep research?

DSIP, delta sleep-inducing peptide, isolated from rabbit blood in 1977 and named for the increase in delta-wave EEG activity its discoverers observed. It has the largest sleep-specific literature of any peptide, spanning several species and small early human studies, but the findings were inconsistent across replications, no receptor has been identified, and the mechanism remains unresolved.

Are sleep peptides approved in Canada?

No. Health Canada has not authorized DSIP, epitalon or any GH-axis peptide as a sleep aid or for any other human use; none has a Drug Identification Number. Its April 2026 public advisory states that peptides are generally regulated as prescription drugs and that unauthorised products have not been assessed for safety, efficacy or quality. Research-labelled peptides are laboratory materials and are not for human use.

What is the difference between DSIP and melatonin?

They are different molecules with different regulatory status. Melatonin is a small indoleamine hormone produced by the pineal gland and is a permitted ingredient in licensed natural health products in Canada. DSIP is a nine-amino-acid peptide with no identified receptor, studied in animal sleep models, with no authorized product anywhere; it is supplied only as a research material for laboratory use.

How is sleep studied with peptides in the laboratory?

Mainly by EEG in animal models: cortical activity is recorded continuously, scored into sleep stages, and the delta-band power during non-REM sleep is compared between compound-treated and vehicle-treated animals. Circadian studies instead sample melatonin and related hormones at fixed times under controlled light–dark cycles to compare rhythm curves. In-vitro work covers receptor binding, stability and gene expression in cultured cells.

All compounds referenced on this page are supplied for laboratory research use only and are not for human or veterinary use. Literature statements summarise published animal-model and early human findings and are not claims about any product. Regulatory statements reflect Health Canada’s public advisory and Drug Product Database as of September 2026. Page last reviewed September 2026.